A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002)
Cancer Chemotherapy and Pharmacology Sep 19, 2017
Ikezawa Y, et al. - Experts planned to select the most suitable regimen as a third- or fourth-line therapy for wild-type EGFR non-small cell lung cancer (NSCLC). As compared to erlotinib, S-1 as a third- or fourth-line therapy for wild-type EGFR NSCLC exhibited numerically better clinical outcomes.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
